This project presents a long/short equity strategy in the China biotech sector, going long BeOne Medicines and short Akeso Inc.. The core thesis is that the market is mispricing execution certainty versus innovation optionality within the same industry cycle.
BeOne represents a commercial-stage biotech with global revenue visibility, strong gross margins, and a de-risked late-stage pipeline, while Akeso remains more dependent on early-stage clinical outcomes and faces binary risks tied to key trial readouts.
The analysis integrates fundamental valuation, pipeline risk assessment, and AI-assisted research, including NLP-based sentiment analysis and pipeline scoring models. Both AI and traditional DCF approaches converge on the same directional view, reinforcing conviction in the trade.
Overall, the strategy captures asymmetric risk-reward, with limited downside for the long position and multiple catalysts driving potential downside for the short position.
